AxoGen, Inc.·Healthcare

SG Americas Securities LLC boosted its position in AxoGen, Inc. (NASDAQ: AXGN) by 459.9% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 65,480 shares of the medical equipment provider's stock after purchasing an additional 53,786 shares during the quarter. SG Americas

JPMorgan Chase and Co. cut its holdings in shares of AxoGen, Inc. (NASDAQ: AXGN) by 44.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 209,003 shares of the medical equipment provider's stock after selling 170,067 shares during the quarter. JPMorgan Chase and

Exchange Traded Concepts LLC lowered its stake in AxoGen, Inc. (NASDAQ: AXGN) by 45.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,897 shares of the medical equipment provider's stock after selling 26,743 shares during the

An Axogen executie reported selling 5,221 shares of Common Stock for a transaction value of approximately $171,000 on March 16, 2026. This represented 1.95% of total holdings as reported in the Form 4; direct holdings, meanwhile, declined from 268,002 to 262,781 shares.

DAFNA Capital Management sold 265,456 AXGN shares in the fourth quarter, with an estimated transaction value of $6.53 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $2.36 million, reflecting both trading activity and price movements.

ArrowMark Colorado Holdings LLC grew its stake in AxoGen, Inc. (NASDAQ: AXGN) by 20.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,958,406 shares of the medical equipment provider's stock after purchasing an additional 332,498 shares during the
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Healthcare
Medical - Devices
451
1986-12-17
0.98